KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up

Key Takeaways Shares of Krystal Biotech (KRYS) gained 3.9% yesterday after the company announced that it had dosed the first patient in a phase I/II study evaluating its eye drop KB801 for the treatment of neurotrophic keratitis (NK), a rare, progressive corneal disease. KB801 is an investigational, redosable eye drop gene therapy developed to offer a novel treatment approach for NK. The therapy is designed to promote the sustained, localized production and secretion of nerve growth factor (NGF) by epitheli ...